An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Rallybio to Present at the Cowen 42nd Annual Health Care Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company, announced that CEO Martin Mackay will participate in a panel discussion on 'Neuromuscular' at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 9:10 a.m. ET. The event will be webcasted live on Rallybio's website, with an archived replay available for 30 days. Since its inception in January 2018, Rallybio aims to develop therapies for severe and rare diseases, focusing on hematology, immuno-inflammation, maternal fetal health, and metabolic disorders.
Positive
None.
Negative
None.
NEW HAVEN, Conn.--(BUSINESS WIRE)--
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Martin Mackay, Ph.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, “Neuromuscular” at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 9:10 a.m. ET.
A webcast of the panel discussion will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. An archived replay of the webcast will be available for 30 days following the conference.
About Rallybio
Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.
